期刊文献+

扎来普隆治疗失眠的临床研究 被引量:2

下载PDF
导出
摘要 目的 评价国产扎来普隆 (zaleplon)治疗失眠的疗效和安全性。方法 对 60例失眠患者进行扎来普隆和佐匹克隆的随机双盲双模拟对照、剂量可调整的研究。其中扎来普隆组 30例 (5~ 1 0mg/d) ,佐匹克隆组30例 (7 5~ 1 5mg/d) ,共治疗 2周。采用睡眠障碍量表 (SDRS)、临床总体评定量表 (CGI)评定临床疗效 ,不良反应量表 (TESS)评定不良反应。结果 扎来普隆组的治疗总有效率为 66 67% ,佐匹克隆组为 70 0 0 %。两组相比差异无显著性 (P >0 0 5)。SDRS评分在治疗结束时均较基线显著减少 (P <0 0 1 )。两组药物不良反应的发生率无显著性差异 (P >0 0 5)。较常见的不良反应为头昏、口干、头痛、恶心等。停药后 ,反弹性失眠较少。结论 扎来普隆与佐匹克隆治疗失眠安全有效 ,不良反应少而轻 。
出处 《云南医药》 CAS 2003年第3期178-180,共3页 Medicine and Pharmacy of Yunnan
  • 相关文献

参考文献11

  • 1甘一方 舒良 等.国产佐匹克隆治疗失眠的疗效观察[J].中华精神科杂志,1998,31(4):252-252.
  • 2李华芳,顾牛范.新型非苯二氮类镇静催眠药扎来普隆[J].中国新药与临床杂志,2000,19(6):695-698. 被引量:13
  • 3胡晓敏.扎莱普隆的研究进展[J].中国临床药理学杂志,2000,16(6):445-447. 被引量:8
  • 4RUSH CR, FREY JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse protential [J]. Psychopharmacology, 1999, 145: 1,39- 51.
  • 5WEITZEL KW, WICKMAN JM, AUGUSTIN SG, et al.Zaleplon: a pyrazolopymidine sedative- hypnotic agent for the treatment of insomnia [J ]. Clin Ther, 2000, 22(11): 1254-1267.
  • 6SANGER D J, MOREL E, PERRAULT G. Comparison of the pharmacological profiles of the hypnotic drugs,zaleplon and zolpidem [J]. Eur J Pharrnacol, 1996, 313(1-2): 35-42.
  • 7ELIE R, RHER E, FARR I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clifiical Study Group [J]. J Clin Psychiatry, 1999, 60: 536-544.
  • 8DROVER D, LEMMENS H, NAIDU S, et al.Pharmacokinetics, pharmacodynamics, and relative pharmacoklinetic/pharmacodynamic profdes of zaleplon and zolpidem [J]. Clin Ther, 2000, 22 (12): 1443- 1461.
  • 9DOOLEY M, PLOSKER GL. Zaleplon: a review of its use in the treatment of insomnia [J ]. Drugs, 2000, 60(2) : 413- 445.
  • 10HOLM ILl, GOA KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia[J]. 2000, 59 (4): 865-889.

二级参考文献16

  • 1[1]Beer. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia. CNS Drug Reviews, 1997; 3: 210~215.
  • 2[2]Sanger DJ ,Morel E,Perrault G.Comparison of the pharmacological profiles of the hypnotic drugs,zaleppon and zolpidem .Eur J Pharmacol, 1996; 313(1~2):35~42.
  • 3[3]Jacques G, France V. Pharmacokinetics and anticonvulsant effect of a new hypnotic ,CL 284,846,in rats. Pharmaceutical Research, 1995; 12: 1592~1597.
  • 4[4]Amy S R, Mona D,et al. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos, 1999; 20:171~175.
  • 5[5]David J G, Jerold S H,et al.Comparative kinetics and dynamics of zaleplon, zolpidem,and placebo.Clinical Pharmacology & Therzpeutics, 1998; 553~560.
  • 6[6]Kimberly E. Vanover, et al,Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic. Psychopharmacology, 1994; 115: 289~296.
  • 7[7]Ator NA, Griffiths RR. Differential generalization to pentobarbital in rats trained to discriminate lorazepam chlordiazepoxide diazepam or triazolam. Psychopharmacology, 1989; 98:20~30.
  • 8[8]Craig R.R. Zaleplon and triazolam in humans:acute behavioral effects and abuse potemtial. Psychopharmacology, 1999; 145: 39~51.
  • 9[9]Walsh J K, Fry J, Evwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clin.Drug Invest, 1998; 16: 347~354.
  • 10Bliwise DL,King AC,Harris RB,Haskell WL.Prevalence of self-reported poor sleep in a healthy population aged 50-65[].Social Science and Medicine.1992

共引文献24

同被引文献29

引证文献2

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部